EcoDrugPlus

Bradykinin Receptor B2

Ensembl ID : ENSHCOG00000019954
Gene Symbol: BDKRB2
1 Cross references
155 Possible Orthologues:

Bradykinin Receptor B2

Ensembl ID : ENSHCOG00000001437
Gene Symbol: BDKRB2
4 Cross references
285 Possible Orthologues:

Camp-Specific 3',5'-Cyclic Phosphodiesterase 4b-Like

Ensembl ID : ENSHCOG00000005189
Gene Symbol: LOC109521263
2 Cross references
224 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSHCOG00000014410
Gene Symbol: CACNA1C
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, L Type, Alpha 1c Subunit

Ensembl ID : ENSHCOG00000014498
Gene Symbol: CACNA1C
1 Cross references
212 Possible Orthologues:

Calcium Channel, Voltage-Dependent, Beta 2a

Ensembl ID : ENSHCOG00000015727
Gene Symbol: CACNB2A
1 Cross references
201 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSHCOG00000001304
Gene Symbol: CASR
3 Cross references
201 Possible Orthologues:

Calcium Sensing Receptor

Ensembl ID : ENSHCOG00000001307
Gene Symbol: CASR
1 Cross references
201 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 1

Ensembl ID : ENSHCOG00000010762
Gene Symbol: CACNA2D1
4 Cross references
226 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 2

Ensembl ID : ENSHCOG00000007758
Gene Symbol: CACNA2D2
1 Cross references
195 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 3

Ensembl ID : ENSHCOG00000002092
Gene Symbol: CACNA2D3
1 Cross references
213 Possible Orthologues:

Calcium Voltage-Gated Channel Auxiliary Subunit Alpha2delta 4

Ensembl ID : ENSHCOG00000009660
Gene Symbol: CACNA2D4
1 Cross references
218 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).